Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Onapristone - Context Therapeutics

Drug Profile

Onapristone - Context Therapeutics

Alternative Names: Apristor; AR-18; ER onapristone; IVV-1001; ONA-XR; Onapristone - Arno Therapeutics; Onapristone extended-release; ZK-299; ZK-98299

Latest Information Update: 30 Apr 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bayer Schering Pharma
  • Developer Arno Therapeutics; Bayer HealthCare Pharmaceuticals; Bayer Schering Pharma; Context Therapeutics; Jefferson Health; Memorial Sloan-Kettering Cancer Center
  • Class Antineoplastics; Antiprogestogens; Dimethylamines; Gonanes; Small molecules
  • Mechanism of Action Progesterone receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Endometrial cancer; Ovarian cancer; Peritoneal cancer; Prostate cancer
  • Phase 0 Breast cancer
  • Discontinued Endometriosis; Pregnancy; Uterine cancer

Most Recent Events

  • 28 Jan 2021 Phase-II clinical trials in Endometrial cancer (Second-line therapy or greater, Combination therapy, Late-stage disease) in USA (PO) (NCT04719273)
  • 15 Jan 2021 Thomas Jefferson University plans a phase II trial in Endometrial cancer (Combination therapy, Second-line therapy or greater) (PO, Tablet) (NCT04719273)
  • 22 Oct 2020 Phase-0 for Breast cancer (Neoadjuvant therapy) in Spain (PO) (NCT04142892)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top